Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 24, 2026.

Interleukin-6: A Novel Target for Cardio-Cerebrovascular Diseases

Jian-Hui Su, Meng-Yi Luo, Na- Liang and 5 more

Frontiers in Pharmacology · 2021 · Review · CC BY

doi:10.3389/fphar.2021.745061

Abstract

Cardio-Cerebrovascular Disease is a collective term for cardiovascular disease and cerebrovascular disease, being a serious threat to human health. A growing number of studies have proved that the content of inflammatory factors or mediators determines the stability of vascular plaque and the incidence of cardio-cerebrovascular event, and involves in the process of Cardio-Cerebrovascular Diseases. Interleukin-6 is a widely used cytokine that causes inflammation and oxidative stress, which would further result in cardiac and cerebral injury. The increased expression of interleukin-6 is closely related to atherosclerosis, myocardial infarction, heart failure and ischemic stroke. It is a key risk factor for these diseases by triggering inflammatory reaction and inducing other molecules release. Therefore, interleukin-6 may become a potential target for Cardio-Cerebrovascular Diseases in the future. This paper is aimed to discuss the expression changes and pathological mechanisms of interleukin-6 in Cardio-Cerebrovascular Diseases, and to provide a novel strategy for the prevention and treatment of Cardio-Cerebrovascular Diseases.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 24, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Cardio-Cerebrovascular Diseases (CCVDs) are the general term of all heart and brain diseases related to vascular diseases, such as atherosclerosis (AS), myocardial infarction (MI), heart failure (HF) and ischemic stroke (IS). CCVDs are common diseases that pose a serious threat to human health, especially to people over 50 years of age. Despite efforts to reduce mortality, CCVDs remain the leading cause of death in the world. It is estimated that approximately 17.3 million people have died from CCVDs each year, accounting for nearly one third of global deaths; also, more than 80 percent of these deaths from CCVDs occur in developing countries. To conclude, CCVDs are characterized by high prevalence, high mortality and disability rates, which not only put heavy economic pressure on families and society but also cause great physical or psychological suffering to individuals, directly adding to the global public health burden and hindering socio-economic development. In the face of such a critical situation, there is an urgent need to explore the pathogenesis of CCVDs as well as new therapeutic targets.

The pathogenesis of CCVDs is complex and multifactorial. CCVDs are known to be inflammatory diseases, and there is a strong link between inflammation and CCVDs. Yudkin et al. Have shown that interleukin-6 (IL-6) and C-reactive protein (CRP) are key factors in the inflammatory reaction of CCVDs. IL-6 was first discovered and cloned in the 1980s by the Kishimoto’s laboratory as a small glycoprotein that can be produced by a variety of cells, and responds to various stimuli. Members of the IL-6 family include IL-11, leukaemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), and novel neurotrophin-1/B cell stimulatory factor-3 (NNT-1/BSF-3), sharing similar signaling pathways and playing important functions in inflammatory diseases, immune disorders and tumors. IL-6, an important member of this family, is considered to be an important pro-inflammatory factor. IL-6 expression is tightly regulated, with low levels of expression in healthy individuals and elevated expression during infection, trauma or other stress. Zamani et al. demonstrated that IL-6 promoted the development and rupture of atherosclerotic plaques. During myocardial ischemia-reperfusion, cardiomyocytes release IL-6, which induces neutrophils and cardiomyocytes to express CD11b/CD18 and intercellular adhesion molecule-1 (ICAM-1), thereby damaging the myocardium. In addition, IL-6 mRNA expression was elevated in a rat model of cerebral ischemia, and elevated IL-6 concentrations in the cerebrospinal fluid of patients with acute stroke was correlated with infarct volume. These studies suggest that the biological functions and mechanisms of IL-6 may play a key role in the pathogenesis of CCVDs.

Collectively, these data indicate that probing the biological functions and mechanisms of IL-6 may play a critical role in the pathogenesis of CCVDs. Our review provides a brief overview of the IL-6, reveals that IL-6 involves in the pathogenesis of CCVDs, and the therapeutic potential of IL-6 in CCVDs.

Secretion and Structure of Interleukin-6

IL-6 comes from a wide range of sources, mainly produced by mononuclear macrophages, T helper 2 cells, B cells, vascular endothelial cells (ECs), smooth muscle cells (SMCs) and fibroblasts. It acts not only on the immune system, but also on the neurological and cardiovascular systems. The human IL-6 gene is located on the short arm of chromosome 7, which is approximately 5 kb in length, including 5 exons and 4 introns. The molecule IL-6 is a glycoprotein with a molecular weight of 26 kDa, composed of 184 amino acids, mediating a variety of biological effects by recognizing and binding to the IL-6 receptor (IL-6R) on the surface of target cells. IL-6R is widely expressed on the surface of various cells and consists of α and β polypeptide chains, namely, the specific binding α-subunit IL-6Rα and the signal-transducing β-subunit glycoprotein 130 (gp130). IL-6 has one binding site to IL-6Rα and two binding sites to gp130 and the final formed ternary complex is a hexamer.

Signal Pathway and Biological Function of Interleukin-6

The combination of IL-6 and IL-6R can activate downstream signal transduction pathways (Figure 1). Through the engagement of unique receptor, IL-6 is able to activate Janus kinase (JAK)-STAT pathway, SHP2-mitogen-activated protein kinase (MAPK) pathway and phosphoinositide 3-kinase (PI3K)-protein kinase B (Akt) pathway, among which, JAK1-STAT3 pathway is the main signaling pathway in the interleukin-6 family of cytokines. IL-6 first binds to IL-6Rα to form a dimer, which is activated by phosphorylation, and then forms an activated trimer complex with gp130, which initiates the intracellular signal cascade and induces the phosphorylation of JAK family related to IL-6R, further activating the downstream transcription factors of STAT family and binding to the promoter region of target genes, to generate a series of essential functions to maintain normal vital movements, such as inflammation, immune responses and cell recruitment (Table 1). Various IL-6 target genes are caused by activation of the transcription factor STAT3, which also stimulates the expression of genes encoding suppressor of cytokine signaling-1 (SOCS1) and SOCS3. In addition, SOCS1 can bind tyrosine-phosphorylated JAK, whereas SOCS3 binds tyrosine-phosphorylated gp130 to terminate IL-6 signaling through a negative feedback loop. The biological functions mediated by IL-6 are very complicated, which mainly include: 1) After the organism is stimulated by tissue injury, infection and inflammation, IL-6 could induce the production of cytokines including acute phase reaction proteins via NF-κB. 2) By activating endothelial cells and increasing the expression of adhesion molecules and the secretion of chemokines, IL-6 induces neutrophils to regroup into the affected tissue. 3) After antigen stimulating B cells, IL-6 could induce B cells to proliferate, differentiate and produce antibodies. 4) IL-6 could also induce the proliferation and differentiation of thymic T cells, activate macrophages and natural killer cells, and participate in the coordination of immune system to resist harmful stimuli. 5) IL-6 is related to tissue fibrosis and vascular endothelial injury, promotes angiogenesis and increases vascular permeability by stimulating the proliferation and migration of circulating endothelial progenitor cells, and also participates in the proliferation and migration of SMCs. Once IL-6 levels are abnormally elevated, the physiological disorder would occur, which leads to a series of pathological changes including inflammatory injury, plaque formation and rupture, and thrombosis. These changes has a promotional effect on the development of CCVDs.

Roles of Interlukin-6 in Cardio-Cerebrovascular Diseases

As an important mediator of the inflammatory reaction, IL-6 acts extensively in the cardio-cerebrovascular system and is involved in the development of cardio-cerebrovascular pathologies. The role of IL-6 and its specific mechanisms in CCVDs would be discussed (Table 2).

Interlukin-6 and Atherosclerosis

AS is an inflammatory disease characterized by progressive lipid accumulation in the arterial wall, inflammation, SMCs infiltration and extracellular matrix remodeling that can lead to multiple clinically CCVDs, such as coronary artery disease, stroke and peripheral arterial diseases. AS begins with endothelial damage, and inflammation is involved in the entire process of AS. In 1994, Seino et al. found that IL-6 was expressed locally in coronary atherosclerotic plaques and in the walls of atherosclerosis-damaged arteries, and the expression was 10–40 times higher than in normal tissue. It has been demonstrated that IL-6 promoted the development and rupture of atherosclerotic plaques, accelerating the progress of AS.

IL-6 has a great many functions, including stimulating hepatic synthesis of acute phase reactants, activating endothelial cells, increasing coagulation, and promoting lymphocyte proliferation and differentiation. The different effects act on the different stages of AS would influence the development, progression and complications of AS (Figure 2). There are several possible pathways that are thought to be involved in the formation and progression of AS by IL-6: 1) IL-6 induces CRP production in the liver to stimulate leukocyte recruitment and promote inflammatory responses in endothelial cells, leading to endothelial dysfunction. 2) IL-6 induces plasma fibrinogen activator inhibitor (PAI) and fibrinogen production in hepatocytes, which increases blood clotting and promotes thrombosis. 3) IL-6-activated macrophages secrete monocyte chemotactic proteins (MCP) to recruit monocytes into the subendothelium to participate in plaque formation. 4) IL-6 induces low-density lipoprotein receptor (LDLR) expression on the surface of macrophages to promote macrophage uptake of low-density lipoprotein (LDL), accelerating lipid deposition and promoting foam cell formation. 5) IL-6 increases the expression of the cell adhesion molecule CD44 in macrophages, however, the high expression of CD44 also increases the secretion of IL-6 from macrophages in a positive feedback loop that exacerbates the progression of AS. 6) IL-6 increases matrix metalloproteinase (MMP) synthesis, degrades the extracellular matrix, and makes plaques prone to rupture. 7) IL-6 increases the expression of vascular cell adhesion molecule-1 (VCAM-1) and ICAM-1, and promotes leukocyte aggregation to exacerbate the inflammatory reaction. 8) IL-6 increases angiotensin II type 1 (AT1) receptor expression in vascular SMCs which exacerbates oxidative stress and endothelial insufficiency that promotes AS progression. 9) IL-6 promotes the differentiation of naive T lymphocytes into helper T lymphocytes (Th) that sustain the spread of the inflammatory reaction. The above findings suggest that IL-6 plays a vital role in the pathology of AS and contributes to the development of AS through multiple pathways.

Interlukin-6 and Myocardial Infarction

MI refers to the ischemic heart disease of cardiomyocyte injury and death caused by acute and persistent ischemia and hypoxia of coronary artery. After MI, there would exist irreversible necrosis due to hypoxia in cardiomyocytes, followed by infiltration of inflammatory cells including neutrophils and monocytes, releasing pro-inflammatory factors such as IL-6, activating their own immune systems, and resulting in severe inflammatory reaction.

One of the causes of MI is the accumulation of atherosclerotic plaques in the coronary artery. Vascular inflammation plays a crucial role in the formation and progression of plaque and rupture of fibrous cap which would trigger the local thrombosis and hypoxia-related myocardial injury. IL-6 signaling is related to the initiation and destabilization of plaque, and also linked to the adverse consequences of acute ischemia. Thus, we speculate that there is a relationship between IL-6 and MI pathogenesis. Recent studies have shown that myocardial remodeling after MI has become the main cause of infarct mortality. IL-6 mediates myocardial remodeling, cardiomyocyte apoptosis and reduction of myocardial contractility by inducing the collection of inflammatory cells in injured myocardium, which is proved once again that IL-6 plays a promoting role in the process of MI. It is reported that IL-6 increased in patients with acute myocardial infarction and reached a peak in about 3 days. In addition, in the animal model, it was found that the serum IL-6 in mice increased significantly within 6 h after myocardial ischemia/reperfusion. This evidence suggests that there is a positive correlation between IL-6 and the risk of myocardial infarction. The level of IL-6 may be an important factor affecting the degree of MI and subsequent cardiac remodeling and function.

According to increasingly related reports and studies, the specific role of IL-6 in MI appears to be gradually clear. Cardiomyocytes produce IL-6 under hypoxic and ischemic stress, express in the infarct border zone after MI, activate JAK/STAT cascade through abundant gp130 signal transduction receptor in cardiomyocytes to exert negative inotropic and cytotoxicity, and through the inflammatory reaction to mediate neutrophil infiltration and activation, release more kinds of cytokines into the blood, co-stimulating vascular endothelium and inducing cardiomyocytes to express ICAM-1 to lead to myocardial fibrosis and ischemia/reperfusion injury, which accelerate myocardial damage and dysfunction. In a word, the inflammatory reaction of MI is related to the induction of cytokines such as IL-6, and the synthesis of IL-6 is an indispensable part of ischemia/reperfusion injury response.

Interlukin-6 and Heart Failure

HF is a syndrome of cardiac circulatory disorder caused by blood stasis in venous system and insufficient blood perfusion in arterial system due to the cardiac systolic and/or diastolic dysfunction. It is not an independent disease, but the final stage of heart disease progression. Immune activation and inflammation contribute to the initiation and development of HF. Inflammation is one of the key pathophysiological mechanisms of HF. In HF, a variety of cells produce inflammatory mediators like IL-6, which is not only a sign of inflammatory activation, but also may induce systolic dysfunction, ventricular dilatation, cardiomyocyte hypertrophy and apoptosis through different mechanisms, directly acting on the pathological process of HF, promoting the progress and deterioration of HF.

During HF, there are hemodynamic changes and oxidative stress, which is a powerful inducer of inflammatory cytokine IL-6. According to Matsumori, IL-6 levels increased in patients with HF. At the same time, some studies have shown that IL-6 spillover in peripheral blood circulation increased with the severity of HF. Additionally, the activity of IL-6 was also markedly increased in HF, accompanied by an increase in gp130 level. In the HF model constructed by ligating the left anterior descending branch of coronary artery in rats, ischemia and hypoxia promoted the production of IL-6. The evidence fully showed that the expression of IL-6 in blood circulation and myocardium from patients with HF was increased, and the level of IL-6 in blood circulation was bound up with the HF progress. Ventricular remodeling mediated by inflammation is an important cause for the onset and deterioration of HF, in which IL-6 regulates the whole inflammatory process and promotes the development of ventricular remodeling. The increase of cardiac IL-6 and IL-6R mRNA levels is also associated with hemodynamic deterioration in patients with advanced HF. Moreover, there is a significant correlation between IL-6 and HF-related mortality. Hence, as one of inflammatory mediators involved in HF, IL-6 triggers and aggravates HF by mediating myocardial remodeling, reducing myocardial contractility and promoting cardiomyocyte apoptosis. The increase of IL-6 expression is in connection with the decrease of coronary flow reserve, ejection fraction and cardiac function, and the progression of HF.

As the activation of inflammatory pathway is a crucial pathological event in the occurrence and development of HF, and IL-6 is one of the most well-characterized and principal cytokines in cardiovascular disease, understanding the specific role of IL-6 in HF counts for the target therapy in HF. Under the stimulation of ischemia and hypoxia, IL-6 binds to its receptor-coupled protein gp130 by autocrine or paracrine, and then transduces signals into cells via JAK/STAT3 signaling pathway, which induces cardiomyocyte hypertrophy and leads to abnormal endothelium-dependent vasodilation, muscular atrophy and left ventricular dysfunction. Finkel et al. found that IL-6 induced nitric oxide-mediated decrease in calcium flux and contractility in ventricular myocytes by increasing nitric oxide synthase, which eventually caused ventricular remodeling. Meléndez et al. found that IL-6 promoted cardiac fibroblasts to synthesize collagen and led to cardiac interstitial fibrosis, which in turn caused ventricular wall sclerosis and HF. IL-6 can also increase the stiffness of cardiomyocytes by reducing actin phosphorylation. To sum up, increased IL-6 could be regarded as a considerable independent predictor for HF, and could also be utilized as a prognostic biomarker in HF.

Interlukin-6 and Ischemic Stroke

IS is one of the leading causes of death and disability worldwide. Inflammation plays a key role in the progression of IS, yet the underlying mechanisms are largely unknown. Studies have shown that cerebral ischemia can disrupt the dynamic balance between pro- and anti-inflammatory responses, and suppressing the inflammatory reaction can reduce brain damage and improve neurological function. IL-6 is low expressed in normal brain tissue but significantly elevated in response to injury, infection, stroke, and inflammation. IL-6 is produced by neurons, oligodendrocytes, astrocytes, and vascular ECs during cerebral ischemia. Microglia are rapidly activated during cerebral ischemia and become key cells in the inflammatory reaction in the brain, secreting pro-inflammatory cytokines such as IL-6, IL-1β and TNF-α, which are involved in microglia-mediated neurological injury. Previous studies have indicated that IL-6 was elevated during IS. IL-6 has several potentially essential functions in the pathogenesis of stroke. Some studies have found that cytokines such as TNF-α, IL-1α/β and IL-6 affect phospholipid metabolism during acute inflammatory reaction under cerebral ischemia, producing arachidonic acid-like substances, ceramides and reactive oxygen species (ROS), which can cause damage to the brain tissue. After vascular occlusion, IL-1 and IL-6 expression increases and acts on vascular endothelial cells to express ICAM-1, P-selectin, and E-selectin, causing leukocyte aggregation and adhesion and mediating the inflammatory cascade to worsen cerebral ischemic injury.

In summary, IL-6 is one of the inflammatory cytokines in central nervous system (CNS) that activates glial cells and causes leukocyte activation to infiltrate CNS. IL-6 causes inflammatory damage during cerebral ischemia and its pathological mechanisms including induction of chemotactic factor expression and synthesis of intracellular adhesion molecules would lead to an inflammatory immune cascade response, in conjunction with a compromised blood-brain barrier that causes leukocyte infiltration.

Interlukin-6 and Other Cardio-Cerebrovascular Diseases

In addition to the four most predominant diseases in the clinic, IL-6 can also affect diabetic cardiomyopathy (DCM) and atrial fibrillation (AF) (Figure 3). DCM is one of the major cardiovascular complications of diabetes by impairing the diastolic and systolic functions of the heart, which eventually leads to HF. The pathogenesis of DCM involves varied mechanisms, of which myocardial fibrosis has been shown to be the main pathological change that reduces cardiac compliance and stiffens heart by producing excess collagen. ) found that IL-6 promoted collagen synthesis in cardiac fibroblasts and led to cardiac interstitial fibrosis. Zhang et al. suggested that IL-6 promoted the development of diabetic myocardial fibrosis by enhancing TGF-β1 and inhibiting miRNA-29 expression, thereby increasing collagen synthesis, and that knockdown of the IL-6 gene attenuated the development of myocardial fibrosis in DCM.

AF is a common clinical arrhythmia with a complex pathogenesis that is not yet fully understood. A meta-analysis showed that high plasma IL-6 levels were associated with a high risk of AF in the general population and of AF recurrence following electrical cardioversion and radiofrequency ablation therapy. concluded that in patients with AF, high IL-6 level is related to thromboembolism and major bleeding and is an independent risk factor for thromboembolic events. Although the mechanism of IL-6 in the pathogenesis of AF is not clear, studies have shown that IL-6 promotes MMP-2 secretion and is linked to left atrial enlargement, which is a known risk factor for AF. Therefore, it is hypothesized that IL-6 may cause AF through left atrial remodeling.

The Therapeutic Potential Role of IL-6 in Cardio-Cerebrovascular Diseases

IL-6 has been shown to play a vital role in chronic inflammatory diseases which is closely related to CCVDs. Down-regulation of IL-6 signaling is considered as a strategy to reduce cardiovascular risk. Secondary analysis from CANTOS suggests that the therapeutic benefit of IL-1 inhibition for cardiovascular disease is associated with a reduction in IL-6 levels. Also, it has been proved that the level of IL-6 was increased in patients with stroke and was correlated with stroke severity. Thus, suppressing the expression of IL-6 may be a potential target for the treatment of CCVDs.

In Atherosclerosis

IL-6 signaling is in connection with atheromatous plaque formation and instability, and plasma IL-6 levels are used as a marker for cardiovascular diseases such as coronary artery disease and AS. In animal experiments, IL-6 administration to ApoE-/- mice fed with normal or high-fat diet was found to exacerbate AS. In addition to the high expression of IL-6, an inducer of STAT3 in atherosclerotic plaques, activation of STAT3 was also detected in plaques, and was associated with the progression of atherosclerotic lesions. STAT3 activation and atherosclerotic lesion development can be inhibited by using an anti-mouse IL-6 receptor antibody (MR16-1). Pro-inflammatory cytokines are known for affecting both the expression of scavenger receptors and the formation of foam cells. IL-6 is expressed in atherosclerotic lesions in macrophage-rich areas and stimulates the inflammatory reaction of macrophages, as well as SMC proliferation and thrombogenic activity. The administration of IL-6 inhibitor (Am80) in ApoE-/- mice was able to suppress scavenger receptor expression and foam cell formation in vitro and prevent AS formation in vivo. A few studies have also shown that IL-6 played a key role in angiotensin II (Ang II)-mediated CD36 expression and Ox-LDL uptake. Consistently, CD36 obtained from ventral macrophages of IL-6-deficient mice is not up-regulated by Ang II stimulation. In brief, these findings suggest that IL-6 is a major factor in plaque formation and instability, and that IL-6 promotes the development of AS, suggesting that inhibition of IL-6 or its receptors may be a novel approach to the prevention and treatment for AS.

In Myocardial Infarction

IL-6 promotes platelet aggregation and thrombosis by stimulating the production of PAI in liver, up-regulates the expression of ICAM-1 in cardiomyocytes to increase the release of oxygen free radicals, and accelerates the decrease of Ca2+ concentration through NO, thereby damaging cardiomyocytes and playing a negative role in MI. In contrast, demonstrated that inhibition of IL-6 gene expression could activate M2 macrophages, induce macrophage polarization and inhibit fibroblast activation to reduce collagen deposition, notably improving myocardial remodeling caused by MI. Held et al. also found that subcutaneous injection of IL-6 antibody could ameliorate left ventricular dysfunction.

In Heart Failure

In HF patients, the increased IL-6 level is a predictive indicator of cardiac function deterioration and is in linkage to the poor prognosis of HF patients. Up-regulated IL-6 promotes cardiac hypertrophy by aggravating mitochondrial dysfunction caused by oxidative stress through gp130/STAT3 signaling pathway, and induces excessive ROS production by regulating mitophagy level and increasing mitophagy-related protein expression, consequently exaggerating cardiomyocyte apoptosis. Besides, IL-6 changes Ca2+-handling and reduces myocardial contractility, resulting in diastolic disturbance and arrhythmia. The accumulation of IL-6 provides an available inflammatory microenvironment for cardiac remodeling and subsequent HF. For this, suppressing the expression of IL-6 in myocardium may be a new way to treat HF. An experiment has proved that the gene deletion of IL-6 is linked to the decrease of cardiac hypertrophy and fibrosis after angiotensin II stimulation in mice model. Plus, found that the administration of MR16-1 could alleviate left ventricular remodeling after coronary artery ligation in LDLR-/- mice. Similarly, in the TAC-induced mice model, IL-6 deletion attenuated left ventricular hypertrophy and dysfunction. Meanwhile, as an inhibitor of IL-6/gp130, raloxifene could ameliorate myocardial remodeling in TAC mice, attenuate HF, and partially maintain cardiac function at the late stage.

Currently, direct evidence concerning IL-6 inhibition on the alleviation of Cerebrovascular Diseases is scarce, but based on the findings described in the previous section, IL-6 is significantly elevated during IS and is involved in the development of IS. Since IL-6 is a very important mediator that is one of inflammatory cytokines in CNS and leads to inflammatory damage, thus, it is reasonable to infer that IL-6 has significant implications for the prevention and treatment of Cerebrovascular Diseases such as IS.

As for the role of IL-6 inhibitors in CCVDs, there are some correlative studies have proved their effects. For instance, Tocilizumab (Actemra), the first humanized monoclonal antibody against IL-6R, plays protective roles by inhibiting the binding of IL-6 to IL-6R and blocking signal transduction, thereby reducing inflammation. Besides, Cheng et al. found that during ischemia/reperfusion injury, tocilizumab competitively bound to IL-6R, suppressed STAT phosphorylation, inhibited cardiomyocyte apoptosis and maintained cardiomyocyte activity by up-regulating the apoptosis-related factor Bax and down-regulating the expression of BCL-2. Additionally, Kleveland et al. showed that tocilizumab inhibited the myocardial inflammatory reaction in patients with non-ST-elevation MI, reduced hs-CRP levels and decreased troponin T release. Moreover, Broch et al. demonstrated that the early administration of IL-6 receptor inhibitor such as tocilizumab on patients with non-ST-elevation MI within 6 h of symptom onset could reduce myocardial necrosis and infarct size. Also, tocilizumab has been well tolerated and has no significant safety concerns. Hence, there is reason to believe that inhibitors of IL-6 have a protective effect against Cardiovascular Diseases.

Conclusion and Prospect

Since the discovery of IL-6, there have been numerous studies on the relationship between IL-6 and various diseases, and major research results have been achieved. Growing studies have made it clear that the level of IL-6 increases in varying degrees in CCVDs including AS, MI, HF and IS (Figure 4), and participates in the occurrence and development of CCVDs under the stimulation of ischemia, hypoxia, oxidative stress, inflammation and vascular occlusion. Inflammation underlies various physiological and pathological processes, and its role in CCVDs is one of the hotspots of recent research. As one of the most considerable defense mechanisms in vivo, inflammation helps our body to fight against infection, injury and tissue destruction. However, once the inflammation is out of control or exists for a long time, a large number of inflammatory cells would gather in the vascular lesion sites, release potential toxic substances, directly damage the heart and brain tissue, finally resulting in cardiomyocyte and neuron edema or even death. Furthermore, inflammation is often accompanied by oxidative stress that generates excessive ROS. The strong oxidative activity is also able to damage normal cell structure, and promotes the progress of CCVDs. Moreover, inflammation during acute phase may directly affect thrombosis. Macrophages, a kind of immune cells, can penetrate damaged vascular endothelium to promote plaque formation and vascular wall fibrosis in the case of immune disorder and excess inflammation, then resulting in vascular lumen occlusion and aggravating ischemia/reperfusion injury. Cytokines release during inflammation also has the ability to alter the normal anticoagulant and pro-fibrinolytic properties of endothelium, especially IL-6, which accelerates fibrinogen production through signal transduction, accordingly promoting thrombosis and reducing myocardial contractility.

IL-6 is an upstream cytokine that reflects the inflammatory reaction, and is also a candidate biomarker for predicting CCVDs risk. By binding to and interacting with its specific receptor IL-6R, IL-6 activates signal transduction receptor complex gp130, and plays a cascade effect on Cardio-Cerebrovascular system, thence participates in CCVDs. In Cardiovascular Diseases, some researchers found that the level of IL-6 in myocardial tissue from MI rats increased greatly. After drugs were given to suppress the IL-6 expression, myocardial collagen deposition decreased and cardiac function was improved. Withal, a study has manifested that there is a correlation between elevated IL-6 levels and cardiovascular mortality. Likewise, in Cerebrovascular Diseases, IL-6 may play a vital role in the diagnosis and prognosis of IS and could be used to predict the size of brain damage. The increase of IL-6 is closely associated with the size of cerebral infarction and the degree of neurological impairment. In the acute stage of cerebral ischemia, IL-6 would further aggravate ischemic injury. In conclusion, IL-6 involves in CCVDs by regulating inflammatory reaction. Although part of the mechanism is not clear yet, it can be predicted that the role of IL-6 in CCVDs would provide a new theoretical basis for the diagnosis, treatment and prognosis evaluation of diseases.

Wherefore, based on the above research foundation, in the future Cardio-Cerebrovascular therapy, IL-6 blockade strategy may provide a new therapeutic potential. Delving into the study concerning relationship between IL-6 and CCVDs and respective pathogenesis, is of great importance for the prevention and treatment of CCVDs. It is believed that with the deepening of related studies and the continuous improvement of detection technologies, anti-IL-6-related drugs or inhibitors would have a broad therapeutic prospect.

References 141

  1. 1.

    Adibhatla R. M. Dempsy R. Hatcher J. F. (2008 ). Integration of Cytokine Biology and Lipid Metabolism in Stroke. Front. Biosci. 13, 1250–1270.

    Not in our library10.2741/2759

  2. 2.

    Akbari M. Hassan-Zadeh V. (2018 ). IL-6 Signalling Pathways and the Development of Type 2 Diabetes. Inflammopharmacology 26 (3), 685–698.

    Not in our library10.1007/s10787-018-0458-0

  3. 3.

    Akita K. Isoda K. Sato-Okabayashi Y. Kadoguchi T. Kitamura K. Ohtomo F. (2017 ). An Interleukin-6 Receptor Antibody Suppresses Atherosclerosis in Atherogenic Mice. Front. Cardiovasc. Med. 4, 84.

    Not in our library10.3389/fcvm.2017.00084

  4. 4.

    Askevold E. T. Gullestad L. Dahl C. P. Yndestad A. Ueland T. Aukrust P. (2014 ). Interleukin-6 Signaling, Soluble Glycoprotein 130, and Inflammation in Heart Failure. Curr. Heart Fail. Rep. 11 (2), 146–155.

    Not in our library10.1007/s11897-014-0185-9

  5. 5.

    Aulin J. Siegbahn A. Hijazi Z. Ezekowitz M. D. Andersson U. Connolly S. J. (2015 ). Interleukin-6 and C-Reactive Protein and Risk for Death and Cardiovascular Events in Patients with Atrial Fibrillation. Am. Heart J. 170 (6), 1151–1160.

    Not in our library10.1016/j.ahj.2015.09.018

  6. 6.

    Barone F. C. Feuerstein G. Z. (1999 ). Inflammatory Mediators and Stroke: New Opportunities for Novel Therapeutics. J. Cereb. Blood Flow Metab. 19 (8), 819–834.

    Not in our library10.1097/00004647-199908000-00001

  7. 7.

    Barton B. E. (1996 ). The Biological Effects of Interleukin 6. Med. Res. Rev. 16 (1), 87–109.

    Not in our library10.1002/(sici)1098-1128(199601)16:1<87::aid-med3>3.0.co;2-q

  8. 8.

    Benjamin E. J. Muntner P. Alonso A. Bittencourt M. S. Callaway C. W. Carson A. P. (2019 ). Heart Disease and Stroke Statistics-2019 Update: A Report from the American Heart Association. Circulation 139 (10), e56–e528.

    Not in our library10.1161/cir.0000000000000659

  9. 9.
    Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control · 2018
    No notice
  10. 10.

    Broch K. Anstensrud A. K. Woxholt S. Sharma K. Tøllefsen I. M. Bendz B. (2021 ). Randomized Trial of Interleukin-6 Receptor Inhibition in Patients with Acute ST-Segment Elevation Myocardial Infarction. J. Am. Coll. Cardiol. 77 (15), 1845–1855.

    Not in our library10.1016/j.jacc.2021.02.049

  11. 11.

    Carlson N. G. Wieggel W. A. Chen J. Bacchi A. Rogers S. W. Gahring L. C. (1999 ). Inflammatory Cytokines IL-1 Alpha, IL-1 Beta, IL-6, and TNF-Alpha Impart Neuroprotection to an Excitotoxin through Distinct Pathways. J. Immunol.: 1950 163 (7), 3963–3968.

    Not in our library

  12. 12.

    Chamorro A. Hallenbeck J. (2006 ). The Harms and Benefits of Inflammatory and Immune Responses in Vascular Disease. Stroke 37 (2), 291–293.

    Not in our library10.1161/01.str.0000200561.69611.f8

  13. 13.

    Chen F. Chen D. Zhao X. Yang S. Li Z. Sanchis D. (2017 ). Interleukin-6 Deficiency Facilitates Myocardial Dysfunction during High Fat Diet-Induced Obesity by Promoting Lipotoxicity and Inflammation. Biochim. Biophys. Acta Mol. Basis Dis. 1863 (12), 3128–3141.

    Not in our library10.1016/j.bbadis.2017.08.022

  14. 14.

    Cheng H. F. Feng Y. Jiang D. M. Tao K. Y. Kong M. J. (2015 ). Protective Function of Tocilizumab in Human Cardiac Myocytes Ischemia Reperfusion Injury. Asian Pac. J. Trop. Med. 8 (1), 48–52.

    Not in our library10.1016/s1995-7645(14)60186-3

  15. 15.

    Dalen J. E. Alpert J. S. Goldberg R. J. Weinstein R. S. (2014 ). The Epidemic of the 20(th) century: Coronary Heart Disease. Am. J. Med. 127 (9), 807–812.

    Not in our library10.1016/j.amjmed.2014.04.015

  16. 16.

    Darvall K. A. Sam R. C. Silverman S. H. Bradbury A. W. Adam D. J. (2007 ). Obesity and Thrombosis. Eur. J. Vasc. Endovasc Surg. 33 (2), 223–233.

    Not in our library10.1016/j.ejvs.2006.10.006

  17. 17.

    Della Corte V. Tuttolomondo A. Pecoraro R. Di Raimondo D. Vassallo V. Pinto A. (2016 ). Inflammation, Endothelial Dysfunction and Arterial Stiffness as Therapeutic Targets in Cardiovascular Medicine. Curr. Pharm. Des. 22 (30), 4658–4668.

    Not in our library10.2174/1381612822666160510124801

  18. 18.

    Di Minno A. Stornaiuolo M. Novellino E. (2019 ). Molecular Scavengers, Oxidative Stress and Cardiovascular Disease. J. Clin. Med. 8 (11).

    Not in our library10.3390/jcm8111895

  19. 19.

    Eddahri F. Denanglaire S. Bureau F. Spolski R. Leonard W. J. Leo O. (2009 ). Interleukin-6/STAT3 Signaling Regulates the Ability of Naive T Cells to Acquire B-Cell Help Capacities. Blood 113 (11), 2426–2433.

    Not in our library10.1182/blood-2008-04-154682

  20. 20.

    El-Adawi H. Deng L. Tramontano A. Smith S. Mascareno E. Ganguly K. (2003 ). The Functional Role of the JAK-STAT Pathway in post-infarction Remodeling. Cardiovasc. Res. 57 (1), 129–138.

    Not in our library10.1016/s0008-6363(02)00614-4

  21. 21.

    Fan Y. Ye J. Shen F. Zhu Y. Yeghiazarians Y. Zhu W. (2008 ). Interleukin-6 Stimulates Circulating Blood-Derived Endothelial Progenitor Cell Angiogenesis In Vitro. J. Cereb. Blood Flow Metab. 28 (1), 90–98.

    Not in our library10.1038/sj.jcbfm.9600509

  22. 22.

    Ferrarese C. Mascarucci P. Zoia C. Cavarretta R. Frigo M. Begni B. (1999 ). Increased Cytokine Release from Peripheral Blood Cells after Acute Stroke. J. Cereb. Blood Flow Metab. 19 (9), 1004–1009.

    Not in our library10.1097/00004647-199909000-00008

  23. 23.

    Finkel M. S. Oddis C. V. Jacob T. D. Watkins S. C. Hattler B. G. Simmons R. L. (1992 ). Negative Inotropic Effects of Cytokines on the Heart Mediated by Nitric Oxide. Science 257 (5068), 387–389.

    Not in our library10.1126/science.1631560

  24. 24.

    Fischer P. Hilfiker-Kleiner D. (2007 ). Survival Pathways in Hypertrophy and Heart Failure: the Gp130-STAT axis. Basic Res. Cardiol. 102 (5), 393–411.

    Not in our library10.1007/s00395-007-0674-z

  25. 25.

    Fuchs M. Hilfiker A. Kaminski K. Hilfiker-Kleiner D. Guener Z. Klein G. (2003 ). Role of Interleukin-6 for LV Remodeling and Survival after Experimental Myocardial Infarction. FASEB J. 17 (14), 2118–2120.

    Not in our library10.1096/fj.03-0331fje

  26. 26.

    Garbers C. Aparicio-Siegmund S. Rose-John S. (2015 ). The IL-6/gp130/STAT3 Signaling axis: Recent Advances towards Specific Inhibition. Curr. Opin. Immunol. 34, 75–82.

    Not in our library10.1016/j.coi.2015.02.008

  27. 27.

    Gauldie J. Richards C. Harnish D. Lansdorp P. Baumann H. (1987 ). Interferon Beta 2/B-Cell Stimulatory Factor Type 2 Shares Identity with Monocyte-Derived Hepatocyte-Stimulating Factor and Regulates the Major Acute Phase Protein Response in Liver Cells. Proc. Natl. Acad. Sci. U S A. 84 (20), 7251–7255.

    Not in our library10.1073/pnas.84.20.7251

  28. 28.

    Grote K. Luchtefeld M. Schieffer B. (2005 ). JANUS under Stress-Rrole of JAK/STAT Signaling Pathway in Vascular Diseases. Vascul Pharmacol. 43 (5), 357–363.

    Not in our library10.1016/j.vph.2005.08.021

  29. 29.

    Gullestad L. Ueland T. Vinge L. E. Finsen A. Yndestad A. Aukrust P. (2012 ). Inflammatory Cytokines in Heart Failure: Mediators and Markers. Cardiology 122 (1), 23–35.

    Not in our library10.1159/000338166

  30. 30.

    Gwechenberger M. Mendoza L. H. Youker K. A. Frangogiannis N. G. Smith C. W. Michael L. H. (1999 ). Cardiac Myocytes Produce Interleukin-6 in Culture and in Viable Border Zone of Reperfused Infarctions. Circulation 99 (4), 546–551.

    Not in our library10.1161/01.cir.99.4.546

  31. 31.

    Hägg D. Sjöberg S. Hultén L. M. Fagerberg B. Wiklund O. Rosengren A. (2007 ). Augmented Levels of CD44 in Macrophages from Atherosclerotic Subjects: a Possible IL-6-CD44 Feedback Loop? Atherosclerosis 190 (2), 291–297.

    Not in our library10.1016/j.atherosclerosis.2006.03.020

  32. 32.

    Halawa B. Salomon P. Jołda-Mydłowska B. Zyśko D. (1999 ). [Levels of Tumor Necrosis Factor (TNF-Alpha) and Interleukin 6 (IL-6) in Serum of Patients with Acute Myocardial Infarction]. Pol. Arch. Med. Wewn 101 (3), 197–203.

    Not in our library

  33. 33.

    Harris T. B. Ferrucci L. Tracy R. P. Corti M. C. Wacholder S. Ettinger W. H. (1999 ). Associations of Elevated Interleukin-6 and C-Reactive Protein Levels with Mortality in the Elderly. Am. J. Med. 106 (5), 506–512.

    Not in our library10.1016/s0002-9343(99)00066-2

  34. 34.

    Hartman J. Frishman W. H. (2014 ). Inflammation and Atherosclerosis: a Review of the Role of Interleukin-6 in the Development of Atherosclerosis and the Potential for Targeted Drug Therapy. Cardiol. Rev. 22 (3), 147–151.

    Not in our library10.1097/crd.0000000000000021

  35. 35.

    Heinrich P. C. Behrmann I. Haan S. Hermanns H. M. Müller-Newen G. Schaper F. (2003 ). Principles of Interleukin (IL)-6-type Cytokine Signalling and its Regulation. Biochem. J. 374, 1–20.

    Not in our library10.1042/bj20030407

  36. 36.
    Inflammatory Biomarkers Interleukin‐6 and C‐Reactive Protein and Outcomes in Stable Coronary Heart Disease: Experiences From the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) Trial · 2017
    Not checked
  37. 37.

    Herrington W. Lacey B. Sherliker P. Armitage J. Lewington S. (2016 ). Epidemiology of Atherosclerosis and the Potential to Reduce the Global Burden of Atherothrombotic Disease. Circ. Res. 118 (4), 535–546.

    Not in our library10.1161/circresaha.115.307611

  38. 38.

    Herrmann O. Tarabin V. Suzuki S. Attigah N. Coserea I. Schneider A. (2003 ). Regulation of Body Temperature and Neuroprotection by Endogenous Interleukin-6 in Cerebral Ischemia. J. Cereb. Blood Flow Metab., 23 406–415.

    Not in our library10.1097/01.wcb.0000055177.5044810.1097/01.wcb.0000055177.50448.fa

  39. 39.

    Hirano T. (1998 ). Interleukin 6 and its Receptor: Ten Years Later. Int. Rev. Immunol. 16, 249–284.

    Not in our library10.3109/08830189809042997

  40. 40.

    Hirano T. Taga T. Yamasaki K. Matsuda T. Yasukawa K. Hirata Y. (1989 ). Molecular Cloning of the cDNAs for Interleukin-6/B Cell Stimulatory Factor 2 and its Receptor. Ann. N. Y Acad. Sci. 557, 167–180. discussion 178-180.

    Not in our library10.1111/j.1749-6632.1989.tb24010.x

  41. 41.

    Hirota H. Izumi M. Hamaguchi T. Sugiyama S. Murakami E. Kunisada K. (2004 ). Circulating Interleukin-6 Family Cytokines and Their Receptors in Patients with Congestive Heart Failure. Heart Vessels 19 (5), 237–241.

    Not in our library10.1007/s00380-004-0770-z

  42. 42.

    Huang J. Upadhyay U. M. Tamargo R. J. (2006 ). Inflammation in Stroke and Focal Cerebral Ischemia. Surg. Neurol. 66 (3), 232–245.

    Not in our library10.1016/j.surneu.2005.12.028

  43. 43.

    Huang M. Yang D. Xiang M. Wang J. (2015 ). Role of Interleukin-6 in Regulation of Immune Responses to Remodeling after Myocardial Infarction. Heart Fail. Rev. 20 (1), 25–38.

    Not in our library10.1007/s10741-014-9431-1

  44. 44.

    Huber S. A. Sakkinen P. Conze D. Hardin N. Tracy R. (1999 ). Interleukin-6 Exacerbates Early Atherosclerosis in Mice. Arterioscler Thromb. Vasc. Biol. 19 (10), 2364–2367.

    Not in our library10.1161/01.atv.19.10.2364

  45. 45.

    Huo S. Shi W. Ma H. Yan D. Luo P. Guo J. (2021 ). Alleviation of Inflammation and Oxidative Stress in Pressure Overload-Induced Cardiac Remodeling and Heart Failure via IL-6/STAT3 Inhibition by Raloxifene. Oxid Med. Cel Longev 2021, 6699054.

    Not in our library10.1155/2021/6699054

  46. 46.

    Ikeda U. Ikeda M. Oohara T. Oguchi A. Kamitani T. Tsuruya Y. (1991 ). Interleukin 6 Stimulates Growth of Vascular Smooth Muscle Cells in a PDGF-dependent Manner. Am. J. Physiol. 260, H1713–H1717.

    Not in our library10.1152/ajpheart.1991.260.5.h1713

  47. 47.

    Iuchi A. Harada H. Tanaka T. (2018 ). IL-6 Blockade for Myocardial Infarction. Int. J. Cardiol. 271, 19–20.

    Not in our library10.1016/j.ijcard.2018.06.068

  48. 48.

    Janssen S. P. Gayan-Ramirez G. Van den Bergh A. Herijgers P. Maes K. Verbeken E. (2005 ). Interleukin-6 Causes Myocardial Failure and Skeletal Muscle Atrophy in Rats. Circulation 111 (8), 996–1005.

    Not in our library10.1161/01.cir.0000156469.96135.0d

  49. 49.

    Jing R. Long T. Y. Pan W. Li F. Xie Q. Y. (2019 ). IL-6 Knockout Ameliorates Myocardial Remodeling after Myocardial Infarction by Regulating Activation of M2 Macrophages and Fibroblast Cells. Eur. Rev. Med. Pharmacol. Sci. 23 (14), 6283–6291.

    Not in our library10.26355/eurrev_201907_18450

  50. 50.

    Jordan S. C. Choi J. Kim I. Wu G. Toyoda M. Shin B. (2017 ). Interleukin-6, A Cytokine Critical to Mediation of Inflammation, Autoimmunity and Allograft Rejection: Therapeutic Implications of IL-6 Receptor Blockade. Transplantation 101 (1), 32–44.

    Not in our library10.1097/tp.0000000000001452

  51. 51.

    Kang Y. M. Ma Y. Elks C. Zheng J. P. Yang Z. M. Francis J. (2008 ). Cross-talk between Cytokines and Renin-Angiotensin in Hypothalamic Paraventricular Nucleus in Heart Failure: Role of Nuclear Factor-kappaB. Cardiovasc. Res. 79 (4), 671–678.

    Not in our library10.1093/cvr/cvn119

  52. 52.

    Keidar S. Heinrich R. Kaplan M. Hayek T. Aviram M. (2001 ). Angiotensin II Administration to Atherosclerotic Mice Increases Macrophage Uptake of Oxidized Ldl: a Possible Role for Interleukin-6. Arterioscler Thromb. Vasc. Biol. 21 (9), 1464–1469.

    Not in our library10.1161/hq0901.095547

  53. 53.

    Kinlay S. Egido J. (2006 ). Inflammatory Biomarkers in Stable Atherosclerosis. Am. J. Cardiol. 98, 2P–8P.

    Not in our library10.1016/j.amjcard.2006.09.014

  54. 54.

    Kinugawa K. Takahashi T. Kohmoto O. Yao A. Aoyagi T. Momomura S. (1994 ). Nitric Oxide-Mediated Effects of Interleukin-6 on [Ca2+]i and Cell Contraction in Cultured Chick Ventricular Myocytes. Circ. Res. 75 (2), 285–295.

    Not in our library10.1161/01.res.75.2.285

  55. 55.

    Kishimoto T. Akira S. Narazaki M. Taga T. (1995 ). Interleukin-6 Family of Cytokines and Gp130. Blood 86 (4), 1243–1254.

    Not in our library10.1182/blood.v86.4.1243.bloodjournal8641243

  56. 56.

    Kishimoto T. (2005 ). Interleukin-6: from Basic Science to Medicine--40 Years in Immunology. Annu. Rev. Immunol. 23, 1–21.

    Not in our library10.1146/annurev.immunol.23.021704.115806

  57. 57.

    Kleveland O. Kunszt G. Bratlie M. Ueland T. Broch K. Holte E. (2016 ). Effect of a Single Dose of the Interleukin-6 Receptor Antagonist Tocilizumab on Inflammation and Troponin T Release in Patients with Non-ST-elevation Myocardial Infarction: a Double-Blind, Randomized, Placebo-Controlled Phase 2 Trial. Eur. Heart J. 37 (30), 2406–2413.

    Not in our library10.1093/eurheartj/ehw171

  58. 58.

    Kobara M. Noda K. Kitamura M. Okamoto A. Shiraishi T. Toba H. (2010 ). Antibody against Interleukin-6 Receptor Attenuates Left Ventricular Remodelling after Myocardial Infarction in Mice. Cardiovasc. Res. 87 (3), 424–430.

    Not in our library10.1093/cvr/cvq078

  59. 59.

    Koh K. K. Han S. H. Quon M. J. (2005 ). Inflammatory Markers and the Metabolic Syndrome: Insights from Therapeutic Interventions. J. Am. Coll. Cardiol. 46 (11), 1978–1985.

    Not in our library10.1016/j.jacc.2005.06.082

  60. 60.

    Kopf M. Baumann H. Freer G. Freudenberg M. Lamers M. Kishimoto T. (1994 ). Impaired Immune and Acute-phase Responses in Interleukin-6-Deficient Mice. Nature 368 (6469), 339–342.

    Not in our library10.1038/368339a0

  61. 61.

    Kukielka G. L. Smith C. W. Manning A. M. Youker K. A. Michael L. H. Entman M. L. (1995 ). Induction of Interleukin-6 Synthesis in the Myocardium. Potential Role in Postreperfusion Inflammatory Injury. Circulation 92 (7), 1866–1875.

    Not in our library10.1161/01.cir.92.7.1866

  62. 62.

    Lambertsen K. L. Biber K. Finsen B. (2012 ). Inflammatory Cytokines in Experimental and Human Stroke. J. Cereb. Blood Flow Metab. 32 (9), 1677–1698.

    Not in our library10.1038/jcbfm.2012.88

  63. 63.

    Lee P. C. Ho I. C. Lee T. C. (2005 ). Oxidative Stress Mediates Sodium Arsenite-Induced Expression of Heme Oxygenase-1, Monocyte Chemoattractant Protein-1, and Interleukin-6 in Vascular Smooth Muscle Cells. Toxicol. Sci. 85 (1), 541–550.

    Not in our library10.1093/toxsci/kfi101

  64. 64.

    Li A. C. Glass C. K. (2002 ). The Macrophage Foam Cell as a Target for Therapeutic Intervention. Nat. Med. 8 (11), 1235–1242.

    Not in our library10.1038/nm1102-1235

  65. 65.

    Lindmark E. Diderholm E. Wallentin L. Siegbahn A. (2001 ). Relationship between Interleukin 6 and Mortality in Patients with Unstable Coronary Artery Disease: Effects of an Early Invasive or Noninvasive Strategy. JAMA 286 (17), 2107–2113.

    Not in our library10.1001/jama.286.17.2107

  66. 66.

    Loddick S. A. Turnbull A. V. Rothwell N. J. (1998 ). Cerebral Interleukin-6 Is Neuroprotective during Permanent Focal Cerebral Ischemia in the Rat. J. Cereb. Blood Flow Metab. 18 (2), 176–179.

    Not in our library10.1097/00004647-199802000-00008

  67. 67.

    Lu L. Q. Tian J. Luo X. J. Peng J. (2021 ). Targeting the Pathways of Regulated Necrosis: a Potential Strategy for Alleviation of Cardio-Cerebrovascular Injury. Cell Mol. Life Sci. 78 (1), 63–78.

    Not in our library10.1007/s00018-020-03587-8

  68. 68.

    Lusis A. J. (2000 ). Atherosclerosis. Nature 407 (6801), 233–241.

    Not in our library10.1038/35025203

  69. 69.

    Madan M. Bishayi B. Hoge M. Amar S. (2008 ). Atheroprotective Role of Interleukin-6 in Diet- And/or Pathogen-Associated Atherosclerosis Using an ApoE Heterozygote Murine Model. Atherosclerosis 197 (2), 504–514.

    Not in our library10.1016/j.atherosclerosis.2007.02.023

  70. 70.

    Maeda K. Tsutamoto T. Wada A. Mabuchi N. Hayashi M. Tsutsui T. (2000 ). High Levels of Plasma Brain Natriuretic Peptide and Interleukin-6 after Optimized Treatment for Heart Failure Are Independent Risk Factors for Morbidity and Mortality in Patients with Congestive Heart Failure. J. Am. Coll. Cardiol. 36 (5), 1587–1593.

    Not in our library10.1016/s0735-1097(00)00912-8

  71. 71.

    Mangan P. R. Harrington L. E. O'Quinn D. B. Helms W. S. Bullard D. C. Elson C. O. (2006 ). Transforming Growth Factor-Beta Induces Development of the T(H)17 Lineage. Nature 441 (7090), 231–234.

    Not in our library10.1038/nature04754

  72. 72.

    Mann D. L. (2002 ). Inflammatory Mediators and the Failing Heart: Past, Present, and the Foreseeable Future. Circ. Res. 91 (11), 988–998.

    Not in our library10.1161/01.res.0000043825.01705.1b

  73. 73.

    Marcus G. M. Whooley M. A. Glidden D. V. Pawlikowska L. Zaroff J. G. Olgin J. E. (2008 ). Interleukin-6 and Atrial Fibrillation in Patients with Coronary Artery Disease: Data from the Heart and Soul Study. Am. Heart J. 155 (2), 303–309.

    Not in our library10.1016/j.ahj.2007.09.006

  74. 74.

    Markousis-Mavrogenis G. Tromp J. Ouwerkerk W. Devalaraja M. Anker S. D. Cleland J. G. (2019 ). The Clinical Significance of Interleukin-6 in Heart Failure: Results from the BIOSTAT-CHF Study. Eur. J. Heart Fail. 21 (8), 965–973.

    Not in our library10.1002/ejhf.1482

  75. 75.

    Martinez-Revelles S. Jiménez-Altayó F. Caracuel L. Pérez-Asensio F. J. Planas A. M. Vila E. (2008 ). Endothelial Dysfunction in Rat Mesenteric Resistance Artery after Transient Middle Cerebral Artery Occlusion. J. Pharmacol. Exp. Ther. 325 (2), 363–369.

    Not in our library10.1124/jpet.107.134619

  76. 76.

    Marx N. Neumann F. J. Ott I. Gawaz M. Koch W. Pinkau T. (1997 ). Induction of Cytokine Expression in Leukocytes in Acute Myocardial Infarction. J. Am. Coll. Cardiol. 30 (1), 165–170.

    Not in our library10.1016/s0735-1097(97)00116-2

  77. 77.

    Matsumori A. Shioi T. Yamada T. Matsui S. Sasayama S. (1994 ). Vesnarinone, a New Inotropic Agent, Inhibits Cytokine Production by Stimulated Human Blood from Patients with Heart Failure. Circulation 89 (3), 955–958.

    Not in our library10.1161/01.cir.89.3.955

  78. 78.

    Medzhitov R. (2008 ). Origin and Physiological Roles of Inflammation. Nature 454 (7203), 428–435.

    Not in our library10.1038/nature07201

  79. 79.

    Meléndez G. C. McLarty J. L. Levick S. P. Du Y. Janicki J. S. Brower G. L. (2010 ). Interleukin 6 Mediates Myocardial Fibrosis, Concentric Hypertrophy, and Diastolic Dysfunction in Rats. Hypertension 56 (2), 225–231.

    Not in our library10.1161/hypertensionaha.109.148635

  80. 80.

    Miyao Y. Yasue H. Ogawa H. Misumi I. Masuda T. Sakamoto T. (1993 ). Elevated Plasma Interleukin-6 Levels in Patients with Acute Myocardial Infarction. Am. Heart J. 126 (6), 1299–1304.

    Not in our library10.1016/0002-8703(93)90526-f

  81. 81.

    Moriya J. (2019 ). Critical Roles of Inflammation in Atherosclerosis. J. Cardiol. 73 (1), 22–27.

    Not in our library10.1016/j.jjcc.2018.05.010

  82. 82.

    Naka T. Narazaki M. Hirata M. Matsumoto T. Minamoto S. Aono A. (1997 ). Structure and Function of a New STAT-Induced STAT Inhibitor. Nature 387 (6636), 924–929.

    Not in our library10.1038/43219

  83. 83.

    Orús J. Roig E. Perez-Villa F. Paré C. Azqueta M. Filella X. (2000 ). Prognostic Value of Serum Cytokines in Patients with Congestive Heart Failure. J. Heart Lung Transpl. 19 (5), 419–425.

    Not in our library10.1016/s1053-2498(00)00083-8

  84. 84.

    Ozova E. M. Kiiakbaev G. K. Kobalava Zh. D. (2007 ). [Inflammation and Chronic Heart Failure. The Role of Statins]. Kardiologiia 47 (1), 52–64.

    Not in our library

  85. 85.

    Paonessa G. Graziani R. De Serio A. Savino R. Ciapponi L. Lahm A. (1995 ). Two Distinct and Independent Sites on IL-6 Trigger Gp 130 Dimer Formation and Signalling. EMBO J. 14 (9), 1942–1951.

    Not in our library10.1002/j.1460-2075.1995.tb07186.x

  86. 86.

    Piepoli M. F. Hoes A. W. Brotons C. Hobbs R. F. D. Corra U. (2018 ). Main Messages for Primary Care from the 2016 European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Eur. J. Gen. Pract. 24 (1), 51–56.

    Not in our library10.1080/13814788.2017.1398320

  87. 87.

    Plenz G. Song Z. F. Tjan T. D. Koenig C. Baba H. A. Erren M. (2001 ). Activation of the Cardiac Interleukin-6 System in Advanced Heart Failure. Eur. J. Heart Fail. 3 (4), 415–421.

    Not in our library10.1016/s1388-9842(01)00137-4

  88. 88.

    Polak M. Doryńska A. Szafraniec K. Pająk A. (2018 ). Cardiovascular Risk Assessment, Cardiovascular Disease Risk Factors, and Lung Function Parameters. Kardiol Pol. 76 (7), 1055–1063.

    Not in our library10.5603/kp.a2018.0055

  89. 89.

    Rattazzi M. Puato M. Faggin E. Bertipaglia B. Zambon A. Pauletto P. (2003 ). C-reactive Protein and Interleukin-6 in Vascular Disease: Culprits or Passive Bystanders? J. Hypertens. 21 (10), 1787–1803.

    Not in our library10.1097/00004872-200310000-00002

  90. 90.

    Rauchhaus M. Doehner W. Francis D. P. Davos C. Kemp M. Liebenthal C. (2000 ). Plasma Cytokine Parameters and Mortality in Patients with Chronic Heart Failure. Circulation 102 (25), 3060–3067.

    Not in our library10.1161/01.cir.102.25.3060

  91. 91.

    Recinos A. LeJeune W. S. Sun H. Lee C. Y. Tieu B. C. Lu M. (2007 ). Angiotensin II Induces IL-6 Expression and the Jak-STAT3 Pathway in Aortic Adventitia of LDL Receptor-Deficient Mice. Atherosclerosis 194 (1), 125–133.

    Not in our library10.1016/j.atherosclerosis.2006.10.013

  92. 92.

    Reddy K. S. Hunter D. J. (2013 ). Noncommunicable Diseases. N. Engl. J. Med. 369 (14), 2563–1343.

    Not in our library10.1056/nejmra110934510.1056/nejmc1313604

  93. 93.

    Ridker P. M. (2016 ). From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream to Identify Novel Targets for Atheroprotection. Circ. Res. 118 (1), 145–156.

    Not in our library10.1161/circresaha.115.306656

  94. 94.

    Ridker P. M. Lüscher T. F. (2014 ). Anti-inflammatory Therapies for Cardiovascular Disease. Eur. Heart J. 35 (27), 1782–1791.

    Not in our library10.1093/eurheartj/ehu203

  95. 95.

    Ridker P. M. MacFadyen J. G. Thuren T. Libby P. (2020 ). Residual Inflammatory Risk Associated with Interleukin-18 and Interleukin-6 after Successful Interleukin-1β Inhibition with Canakinumab: Further Rationale for the Development of Targeted Anti-cytokine Therapies for the Treatment of Atherothrombosis. Eur. Heart J. 41 (23), 2153–2163.

    Not in our library10.1093/eurheartj/ehz542

  96. 96.

    Romano M. Sironi M. Toniatti C. Polentarutti N. Fruscella P. Ghezzi P. (1997 ). Role of IL-6 and its Soluble Receptor in Induction of Chemokines and Leukocyte Recruitment. Immunity 6 (3), 315–325.

    Not in our library10.1016/s1074-7613(00)80334-9

  97. 97.

    Rose-John S. (2017 ). The Soluble Interleukin 6 Receptor: Advanced Therapeutic Options in Inflammation. Clin. Pharmacol. Ther. 102 (4), 591–598.

    Not in our library10.1002/cpt.782

  98. 98.

    Ross R. (1993 ). The Pathogenesis of Atherosclerosis: a Perspective for the 1990s. Nature 362 (6423), 801–809.

    Not in our library10.1038/362801a0

  99. 99.

    Ruiz-Ruiz F. J. Ruiz-Laiglesia F. J. Lasierra P. Perez-Calvo J. I. (2006 ). Time-course of Changes in Levels of Interleukin 6 in Acutely Decompensated Heart Failure. Int. J. Cardiol. 112 (1), 112–113. author reply 113.

    Not in our library10.1016/j.ijcard.2005.06.061

  100. 100.

    Sakamoto T. Yasue H. Ogawa H. Misumi I. Masuda T. (1992 ). Association of Patency of the Infarct-Related Coronary Artery with Plasma Levels of Plasminogen Activator Inhibitor Activity in Acute Myocardial Infarction. Am. J. Cardiol. 70 (3), 271–276.

    Not in our library10.1016/0002-9149(92)90603-v

  101. 101.

    Schett G. Elewaut D. McInnes I. B. Dayer J. M. Neurath M. F. (2013 ). How Cytokine Networks Fuel Inflammation: Toward a Cytokine-Based Disease Taxonomy. Nat. Med. 19 (7), 822–824.

    Not in our library10.1038/nm.3260

  102. 102.

    Schieffer B. Schieffer E. Hilfiker-Kleiner D. Hilfiker A. Kovanen P. T. Kaartinen M. (2000 ). Expression of Angiotensin II and Interleukin 6 in Human Coronary Atherosclerotic Plaques: Potential Implications for Inflammation and Plaque Instability. Circulation 101 (12), 1372–1378.

    Not in our library10.1161/01.cir.101.12.1372

  103. 103.

    Schieffer B. Selle T. Hilfiker A. Hilfiker-Kleiner D. Grote K. Tietge U. J. (2004 ). Impact of Interleukin-6 on Plaque Development and Morphology in Experimental Atherosclerosis. Circulation 110 (22), 3493–3500.

    Not in our library10.1161/01.cir.0000148135.08582.97

  104. 104.

    Schmidt-Arras D. Rose-John S. (2016 ). IL-6 Pathway in the Liver: From Physiopathology to Therapy. J. Hepatol. 64 (6), 1403–1415.

    Not in our library10.1016/j.jhep.2016.02.004

  105. 105.

    Schuett H. Luchtefeld M. Grothusen C. Grote K. Schieffer B. (2009 ). How Much Is Too Much? Interleukin-6 and its Signalling in Atherosclerosis. Thromb. Haemost. 102 (2), 215–222.

    Not in our library10.1160/th09-05-0297

  106. 106.

    Seino Y. Ikeda U. Ikeda M. Yamamoto K. Misawa Y. Hasegawa T. (1994 ). Interleukin 6 Gene Transcripts Are Expressed in Human Atherosclerotic Lesions. Cytokine 6 (1), 87–91.

    Not in our library10.1016/1043-4666(94)90013-2

  107. 107.

    Shu J. Ren N. Du J. B. Zhang M. Cong H. L. Huang T. G. (2007 ). Increased Levels of Interleukin-6 and Matrix Metalloproteinase-9 Are of Cardiac Origin in Acute Coronary Syndrome. Scand. Cardiovasc. J. 41 (3), 149–154.

    Not in our library10.1080/14017430601164263

  108. 108.

    Smart N. Mojet M. H. Latchman D. S. Marber M. S. Duchen M. R. Heads R. J. (2006 ). IL-6 Induces PI 3-kinase and Nitric Oxide-dependent protection and Preserves Mitochondrial Function in Cardiomyocytes. Cardiovasc. Res. 69 (1), 164–177.

    Not in our library10.1016/j.cardiores.2005.08.017

  109. 109.

    Soeki T. Sata M. (2016 ). Inflammatory Biomarkers and Atherosclerosis. Int. Heart J. 57 (2), 134–139.

    Not in our library10.1536/ihj.15-346

  110. 110.

    Souza J. R. Oliveira R. T. Blotta M. H. Coelho O. R. (2008 ). Serum Levels of Interleukin-6 (Il-6), Interleukin-18 (Il-18) and C-Reactive Protein (CRP) in Patients with Type-2 Diabetes and Acute Coronary Syndrome without ST-Segment Elevation. Arq Bras Cardiol. 90 (2), 86–90.

    Not in our library10.1590/s0066-782x2008000200004

  111. 111.
    Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease · 2019
    No notice
  112. 112.

    Suzuki H. Kusuyama T. Sato R. Yokota Y. Tsunoda F. Sato T. (2008 ). Elevation of Matrix Metalloproteinases and Interleukin-6 in the Culprit Coronary Artery of Myocardial Infarction. Eur. J. Clin. Invest. 38 (3), 166–173.

    Not in our library10.1111/j.1365-2362.2007.01919.x

  113. 113.

    Suzuki S. Tanaka K. Nagata E. Ito D. Dembo T. Fukuuchi Y. (1999 ). Cerebral Neurons Express Interleukin-6 after Transient Forebrain Ischemia in Gerbils. Neurosci. Lett. 262 (2), 117–120.

    Not in our library10.1016/s0304-3940(99)00051-8

  114. 114.

    Takeda N. Manabe I. Shindo T. Iwata H. Iimuro S. Kagechika H. (2006 ). Synthetic Retinoid Am80 Reduces Scavenger Receptor Expression and Atherosclerosis in Mice by Inhibiting IL-6. Arterioscler Thromb. Vasc. Biol. 26 (5), 1177–1183.

    Not in our library10.1161/01.atv.0000214296.94849.1c

  115. 115.

    Tanaka T. Kishimoto T. (2012 ). Targeting Interleukin-6: All the Way to Treat Autoimmune and Inflammatory Diseases. Int. J. Biol. Sci. 8 (9), 1227–1236.

    Not in our library10.7150/ijbs.4666

  116. 116.

    Tanaka T. Narazaki M. Kishimoto T. (2016 ). Immunotherapeutic Implications of IL-6 Blockade for Cytokine Storm. Immunotherapy 8 (8), 959–970.

    Not in our library10.2217/imt-2016-0020

  117. 117.

    Tanaka T. Narazaki M. Kishimoto T. (2018 ). Interleukin (IL-6) Immunotherapy. Cold Spring Harb Perspect. Biol. 10 (8).

    Not in our library10.1101/cshperspect.a028456

  118. 118.

    Taniguchi K. Karin M. (2014 ). IL-6 and Related Cytokines as the Critical Lynchpins between Inflammation and Cancer. Semin. Immunol. 26 (1), 54–74.

    Not in our library10.1016/j.smim.2014.01.001

  119. 119.

    Tarkowski E. Rosengren L. Blomstrand C. Wikkelsö C. Jensen C. Ekholm S. (1995 ). Early Intrathecal Production of Interleukin-6 Predicts the Size of Brain Lesion in Stroke. Stroke 26 (8), 1393–1398.

    Not in our library10.1161/01.str.26.8.1393

  120. 120.

    Tsujinaka T. Fujita J. Ebisui C. Yano M. Kominami E. Suzuki K. (1996 ). Interleukin 6 Receptor Antibody Inhibits Muscle Atrophy and Modulates Proteolytic Systems in Interleukin 6 Transgenic Mice. J. Clin. Invest. 97 (1), 244–249.

    Not in our library10.1172/jci118398

  121. 121.

    Tsutamoto T. Hisanaga T. Wada A. Maeda K. Ohnishi M. Fukai D. (1998 ). Interleukin-6 Spillover in the Peripheral Circulation Increases with the Severity of Heart Failure, and the High Plasma Level of Interleukin-6 Is an Important Prognostic Predictor in Patients with Congestive Heart Failure. J. Am. Coll. Cardiol. 31 (2), 391–398.

    Not in our library10.1016/s0735-1097(97)00494-4

  122. 122.

    Unver N. McAllister F. (2018 ). IL-6 Family Cytokines: Key Inflammatory Mediators as Biomarkers and Potential Therapeutic Targets. Cytokine Growth Factor. Rev. 41, 10–17.

    Not in our library10.1016/j.cytogfr.2018.04.004

  123. 123.

    Villegas S. Villarreal F. J. Dillmann W. H. (2000 ). Leukemia Inhibitory Factor and Interleukin-6 Downregulate Sarcoplasmic Reticulum Ca2+ ATPase (SERCA2) in Cardiac Myocytes. Basic Res. Cardiol. 95 (1), 47–54.

    Not in our library10.1007/s003950050007

  124. 124.
    Inflammation, Autophagy, and Apoptosis After Myocardial Infarction · 2018
    Not checked
  125. 125.

    Wang X. (2005 ). Investigational Anti-inflammatory Agents for the Treatment of Ischaemic Brain Injury. Expert Opin. Investig. Drugs 14 (4), 393–409.

    Not in our library10.1517/13543784.14.4.393

  126. 126.

    Wang Y. Meng R. Liu G. Cao C. Chen F. Jin K. (2019 ). Intracranial Atherosclerotic Disease. Neurobiol. Dis. 124, 118–132.

    Not in our library10.1016/j.nbd.2018.11.008

  127. 127.

    Wassmann S. Stumpf M. Strehlow K. Schmid A. Schieffer B. Böhm M. (2004 ). Interleukin-6 Induces Oxidative Stress and Endothelial Dysfunction by Overexpression of the Angiotensin II Type 1 Receptor. Circ. Res. 94 (4), 534–541.

    Not in our library10.1161/01.res.0000115557.25127.8d

  128. 128.

    Westermeier F. Riquelme J. A. Pavez M. Garrido V. Díaz A. Verdejo H. E. (2016 ). New Molecular Insights of Insulin in Diabetic Cardiomyopathy. Front. Physiol. 7, 125.

    Not in our library10.3389/fphys.2016.00125

  129. 129.

    Wolf J. Rose-John S. Garbers C. (2014 ). Interleukin-6 and its Receptors: a Highly Regulated and Dynamic System. Cytokine 70 (1), 11–20.

    Not in our library10.1016/j.cyto.2014.05.024

  130. 130.

    Wu N. Xu B. Xiang Y. Wu L. Zhang Y. Ma X. (2013 ). Association of Inflammatory Factors with Occurrence and Recurrence of Atrial Fibrillation: a Meta-Analysis. Int. J. Cardiol. 169 (1), 62–72.

    Not in our library10.1016/j.ijcard.2013.08.078

  131. 131.

    Yamauchi-Takihara K. Ihara Y. Ogata A. Yoshizaki K. Azuma J. Kishimoto T. (1995 ). Hypoxic Stress Induces Cardiac Myocyte-Derived Interleukin-6. Circulation 91 (5), 1520–1524.

    Not in our library10.1161/01.cir.91.5.1520

  132. 132.

    Yao X. Huang J. Zhong H. Shen N. Faggioni R. Fung M. (2014 ). Targeting Interleukin-6 in Inflammatory Autoimmune Diseases and Cancers. Pharmacol. Ther. 141 (2), 125–139.

    Not in our library10.1016/j.pharmthera.2013.09.004

  133. 133.

    Yilmaz G. Granger D. N. (2008 ). Cell Adhesion Molecules and Ischemic Stroke. Neurol. Res. 30 (8), 783–793.

    Not in our library10.1179/174313208x341085

  134. 134.

    Yndestad A. Damås J. K. Oie E. Ueland T. Gullestad L. Aukrust P. (2006 ). Systemic Inflammation in Heart Failure-Tthe Whys and Wherefores. Heart Fail. Rev. 11 (1), 83–92.

    Not in our library10.1007/s10741-006-9196-2

  135. 135.

    Yudkin J. S. Kumari M. Humphries S. E. Mohamed-Ali V. (2000 ). Inflammation, Obesity, Stress and Coronary Heart Disease: Is Interleukin-6 the Link? Atherosclerosis 148 (2), 209–214.

    Not in our library10.1016/s0021-9150(99)00463-3

  136. 136.

    Yudkin J. S. Stehouwer C. D. Emeis J. J. Coppack S. W. (1999 ). C-reactive Protein in Healthy Subjects: Associations with Obesity, Insulin Resistance, and Endothelial Dysfunction: a Potential Role for Cytokines Originating from Adipose Tissue? Arterioscler Thromb. Vasc. Biol. 19 (4), 972–978.

    Not in our library10.1161/01.atv.19.4.972

  137. 137.

    Zamani P. Schwartz G. G. Olsson A. G. Rifai N. Bao W. Libby P. (2013 ). Inflammatory Biomarkers, Death, and Recurrent Nonfatal Coronary Events after an Acute Coronary Syndrome in the MIRACL Study. J. Am. Heart Assoc. 2 (1), e003103.

    Not in our library10.1161/jaha.112.003103

  138. 138.

    Zhang J. Cheng X. Liao Y. H. Lu B. Yang Y. Li B. (2005 ). Simvastatin Regulates Myocardial Cytokine Expression and Improves Ventricular Remodeling in Rats after Acute Myocardial Infarction. Cardiovasc. Drugs Ther. 19 (1), 13–21.

    Not in our library10.1007/s10557-005-6893-3

  139. 139.

    Zhang P. Dong G. Sun B. Zhang L. Chen X. Ma N. (2011 ). Long-term Exposure to Ambient Air Pollution and Mortality Due to Cardiovascular Disease and Cerebrovascular Disease in Shenyang, China. PloS one 6 (6), e20827.

    Not in our library10.1371/journal.pone.0020827

  140. 140.

    Zhang Y. Huang X. R. Wei L. H. Chung A. C. Yu C. M. Lan H. Y. (2014 ). miR-29b as a Therapeutic Agent for Angiotensin II-Induced Cardiac Fibrosis by Targeting TGF-β/Smad3 Signaling. Mol. Ther. 22 (5), 974–985.

    Not in our library10.1038/mt.2014.25

  141. 141.

    Zhao L. Cheng G. Jin R. Afzal M. R. Samanta A. Xuan Y. T. (2016 ). Deletion of Interleukin-6 Attenuates Pressure Overload-Induced Left Ventricular Hypertrophy and Dysfunction. Circ. Res. 118 (12), 1918–1929.

    Not in our library10.1161/circresaha.116.308688

Cited by papers we hold 1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.